Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy

International Journal of Cancer

Volumn 123, Issue 5, 2008, Pages 1100-1107

  Martorelli, Debora ^a   Houali, Karim ^b   Caggiari, Laura ^a   Vaccher, Emanuela ^a   Barzan, Luigi ^c   Franchin, Giovanni ^a   Gloghini, Annunziata ^a   Pavan, Alessandro ^a   Da Ponte, Alessandro ^a   Tedeschi, Rosa Maria ^a   De Re, Valli ^a   Carbone, Antonino ^d   Ooka, Tadamasa ^b   De Paoli, Paolo ^a   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITÉ LYON 1   (France)

^c Azienda Ospedaliera   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BARF1; Epstein barr virus; Immunotherapy; Nasopharyngeal carcinoma

Indexed keywords

ALANYLPHENYLALANYLLEUCYLGLYCYLGLUTAMYLARGINYLVALYLTHREONYLLEUCINE; ARGINYLPHENYLALANYLISOLEUCYLALANYLGLUTAMINYLLEUCYLLEUCYLLEUCYLLEUCINE; BARF1 PROTEIN; EPITOPE; GAMMA INTERFERON; GLUTAMINYLLEUCYLLEUCYLLEUCYLLEUCYLALANYLSERYLCYSTEINYLVALINE; LEUCYLLEUCYLALANYLSERYLCYSTEINYLVALYLALANYLALANYLGLYCINE; LEUCYLLEUCYLLEUCYLALANYLSERYLCYSTEINYLVALYLALANYLALANINE; LEUCYLLEUCYLLEUCYLLEUCYLALANYLSERYLCYSTEINYLVALYLALANINE; LYSYLLEUCYLGLYCYLPROLYLGLYCYLGLUTAMYLGLUTAMYLGLUTAMINYLVALINE; PEPTIDE; PHENYLALANYLISOLEUCYLALANYLGLUTAMINYLLEUCYLLEUCYLLEUCYLLEUCYLALANINE; PHENYLALANYLLEUCYLGLYCYLGLUTAMYLARGINYLVALYLTHREONYLLEUCYLTHREONINE; PROTEIN; RECOMBINANT PROTEIN; THREONYLLEUCYLTHREONYLSERYLTYROSYLTRYPTOPHYLARGINYLARGINYLVALINE; BARF1 PROTEIN, HUMAN HERPESVIRUS 4; VIRUS PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE CULTURE; NASOPHARYNX CARCINOMA; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA; CARCINOMA; IMMUNOLOGY; ITALY; METABOLISM; METHODOLOGY; NASOPHARYNX TUMOR;

CARCINOMA; EPITOPES; HUMANS; IMMUNOTHERAPY; ITALY; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 47249092365     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23621     Document Type: Article

References (29)

1. International Agency for Research on Cancer. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans. Vol 70. Lyon, France: WHO, 1997.
2. Dolcetti R, Menezes J. Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association. Adv Cancer Res 2003;87:127-57.
3. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997;15:405-31.
4. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998;28:451-8.
5. Lee SP, Chan AT, Cheung ST, Thomas WA, CroomCarter D, Dawson CW, Tsai CH, Leung SF, Johnson PJ, Huang DP. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000;165:573-82.
6. Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, Chen CL, Chang YS, Lee SP, Rickinson AB, Tam PK. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002;62:6952-8.
7. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005;23:8942-9.
8. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005;105:1898-904.
9. Decaussin G, Sbih-Lammali F, De Turenne-Tessier M, Bouguermouh A, Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000;60:5584-8.
10. Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, Takada K. Epstein-Barr Virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 2005;76:82-8.
11. Ooka T. Malignant transformation and immortalization assays in animal cells transfected with the BARF1 gene. Methods Mol Biol 2001;174:147-54.
12. Wei MX, de Turenne-Tessier M, Decaussin G, Benet G, Ooka T. Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene 1997;14:3073-81.
13. Wei MX, Ooka T. A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J 1989;8:2897-903.
14. Wei MX, Moulin JC, Deacussin G, Berger F, Ooka T. Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte cell line. Cancer Res 1994;54:1843-8.
15. Strockbine LD, Cohen JI, Farrah T, Lyman SD, Wagener F, DuBose RF, Armitage RJ, Spriggs MK. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J Virol 1998;72:4015-21.
16. Sall A, Caserta S, Jolicoeur P, Franqueville L, de Turenne-Tessier M. Ooka T. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. Oncogene 2004;23:4938-44.
17. de Turenne-Tessier M, Jolicoeur P, Middeldorp JM, Ooka T. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system. Virus Res 2005;109:9-18.
18. Cohen JI, Lekstrom K. Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol 1999;73:7627-32.
19. Tanner JE, Wei MX, Alfieri C, Ahmad A, Taylor P, Ooka T, Menezes J. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J Infect Dis 1997;175:38-46.
20. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005. 85-97.
21. Sheng W, Decaussin G, Sumner S, Ooka T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene 2001;20:1176-85.
22. Mould RF, Tai TH. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol 2002;75:307-39.
23. Zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 2000;60:2745-8.
24. Dionne SO, Smith MH, Marincola FM, Lake DF. Functional characterization of CTL against gp100 altered peptide ligands. Cancer Immunol Immunother 2003;52:199-206.
25. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004;113:425-33.
26. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr Virus-induced cytotoxic T cell response. J Exp Med 1997;185:1605-17.
27. Pudney VA, Leese AM, Rickinson AB, Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 2005;201:349-60.
28. Zhang JX, Chen HL, Zong YS, Chan KH, Middeldrop JM, Sham JS, Griffin BE, Ng MH. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 1998;55:227-33.
29. Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, Johnson PJ. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 2002;67:359-63.